Feeling bad about the holidays shopping frenzy?

Giving Tuesday is your opportunity to give back… This is a day dedicated to generosity just as Black Friday and Cyber Monday are dedicated to shopping. Contributing to our cause will help someone afflicted Duchenne muscular dystrophy (DMD). It’s the moment in Canada and the whole world to celebrate giving back and supporting causes that matter to you. We are part of the 3,200, charities and organization celebrating this day in Canada.

 

Help someone afflicted Duchenne muscular dystrophy (DMD)

What is Duchenne? It’s a degenerative muscle disease, afflicting mostly young boys 1-3500. It’s a fatal disease with no cure, taking muscles strength away and leaving young adults in a wheelchair and premature death in their twenties. Many treatments are on the horizon, but we need your help to raise awareness and funds… Because there is no time to lose for people afflicted with DMD. Our organization raise funds for promising research and raise awareness to have a unified DMD community across Canada to access new treatment quickly.

 

Give to La Force here

About GivingTuesday

GivingTuesday was launched in Canada in 2013 by GIV3 and CanadaHelps.org and lists 15 founding partners. It’s a day for the entire charitable sector and encourages all Canadians to join the movement and give and volunteer for charities of their choice. GivingTuesday was initially founded in 2012 in the US by 92Y and the UN Foundation.

How to contribute to our cause:

There is no small amount!

Our organization aim to unite the DMD community to raise awareness around a common objective: that of providing access to new treatments as fast as possible and to participate in the funding of promising research projects. We also raise funds for two promising research based in Canada.

 

Every dollar is taking us closer to find better treatments and the cure.

Give to La Force here

 

Other ways to support us:

  • Organize a fundraiser or a sporting event
  • Buy our promotional items to make gifts
  • Share our stories, video and article
  • Display our colours during your outings and events.

 

http://givingtuesday.ca/fr/partners/18244

News

2017, November 17th

On a regular basis, team La Force will relay breaking news to the DMD community in News! our latest blog. We provide news highlights to give you quick-and-easy access to the most recent information about what’s happening worldwide in DMD advocacy and, more importantly, advances in therapy and the availability of new treatments. The short news alerts will also appear in our newsletter and, for members of our DMD community, on the Sign-in page.

The DMD News helps you to stay informed, become aware and share what’s happening in the DMD community to bring us closer to a cure.

 

Be aware. Get involved. Share.

 

Jesse’s Journey & Max’s Big Ride fund STAT3 inhibitor research

On October 31, 2017, Jesse’s Journey and Max’s Big Ride – two non-profit groups founded by parents of children with Duchenne muscular dystrophy (DMD) – presented $336,000 in funding to Dr. Patrick Gunning, Professor of Chemistry, Canada Research Chair in Medicinal Chemistry  Tier II, and head of the Gunning Group, a research laboratory at the University of Toronto Mississauga.

Max’s Big Ride raised $35,000 for Max’s Big Fellowship, a new Ph.D. fellowship at the Gunning Group. It was awarded to Yasir Raouf, who will study STAT3 inhibitors in DMD. Earlier this year, Jesse’s Journey approved a $300,000 grant to Dr. Gunning to fund an exciting, first-time, preclinical study of STAT3 and other protein inhibitors to treat DMD.

For more information about the study and how you can get involved: read here

 


Duke University and Sarepta hunt for gene-editing therapy

Muscular Dystrophy News Today reports that Sarepta Therapeutics has teamed up with Dr. Charles Gersbach’s biomedical engineering laboratory at Duke University to develop gene-editing therapies for Duchenne muscular dystrophy (DMD).

Dr. Gersbach is a pioneer in the use of CRISPR/Cas9 technology, a gene-editing tool that can remove abnormal parts of the dystrophin gene. Mutations in this gene cause DMD. Gerbach says that cutting out specific exons (regions that contain the genetic code or “blueprint” for the dystrophin protein) “has the potential to correct a majority of DMD mutations.”

His team has already shown, in mice models of DMD, that removing abnormal regions of the dystrophin gene restores muscle function. The edited gene was able to produce a normally functioning protein that improved muscle strength in mice.

For more information: read here

 


New clinical trial of exon-51 skipping therapy for DMD

Wave Life Sciences has begun the first clinical trial of WVE-210201, an exon 51-skipping therapy, in patients with Duchenne muscular dystrophy (DMD). The multicenter, double-blinded, placebo-controlled, dose-finding, Phase 1 clinical trial will study which intravenous doses of WVE-210201 are safe and tolerable in a subgroup of patients with DMD. About 13% of patients with DMD have exon 51 mutations in the dystrophin gene.

The study will enroll up to 40 patients between 5 and 18 years of age, either able or unable to walk. It will begin in the USA, then expand to Europe and other regions. Results are expected in late 2018.

WVE-210201 is an antisense oligonucleotide that throws a cog in the wheels of protein manufacturing. It forces the cellular machinery to skip over a damaged exon – a specific section of genetic code – then resume regular “reading” of the protein’s “blueprint.” The exon 51-skipping process produces an incomplete but functional dystrophin protein, which may restore some muscle function in patients with this mutation.

For more information: read here

 

Ride for a cure with Dystrospin

On Sunday, November 19, from 7 am to 5 pm, Dystrospin and La Force invite you to spin for Duchenne Muscular Dystrophy. Since 2016, La Fondation La Force has been associated with this event, organized by the Morand family for over five years. All proceeds from the Dystrospin will be donated to two researchers based here in Québec. They are Dr. Jacques Tremblay for his research on CRISPR-Cas9 and Dr. Jérôme Frenette for his research on Osteoprotegerin.

 

For the love of his son…

Jean-Philippe Morand, whose 11-year-old son, Victor, has DMD, will be directing 10 consecutive spinning sessions. The bravest participants will have the opportunity to pedal 10 in a row.

 

An event for everyone

Whether you’re a beginner or experienced, it’s sure to be a pleasurable experience, and above all, a unique chance to test your limits. On site, volunteers will help you adjust your bike and explain the training instructions. For the young ones, daycare service will be offered free of charge for the duration of your participation in the event. Inflatable games, drawing, ball games, etc.: you can bet they’ll have a good time! The little ones are also more than welcome.

 

Every action counts

Duchenne muscular dystrophy is a degenerative disease of the muscles that mainly affects young boys and is 100% fatal. The progression of the disease is unforgiving: the body’s muscles weaken little by little, leaving boys in a wheelchair at the age of 12, with a life expectancy of 20 to 30 years. Nowadays, there is hope through research, and several new treatments are on the horizon. This hope motivates Jean-Philippe to exceed his limits for his son. Every gesture made to raise awareness for the disease will help us fund research and access to new treatments.

 

How to participate

The activity will take place at PerformanceC2. The Centre is located at Place St-Nicolas, 845, Marie-Victorin in St-Nicolas. Since the number of stationary bikes is limited, you must reserve your bike at for a time that suits you.

Registration and online payment on our highly secure site can be found here> https://www.jedonneenligne.org/fondationchudequebec/frm_detail.php?FrmUID=134

 

If you can’t participate in this activity? You can still donate here

 

Learn more: